Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Jefferies lifts CytomX Therapeutics stock target to $2.50, maintains hold

EditorNatashya Angelica
Published 12/03/2024, 17:22
© Reuters.
CTMX
-

On Tuesday, an analyst from Jefferies updated their outlook on shares of CytomX Therapeutics (NASDAQ:CTMX), increasing the stock price target to $2.50 from the previous $1.60. The firm kept a Hold rating on the stock. The revision follows a recent meeting with the company's management after their earnings report.

The progress of CytomX's pipeline was the focal point of the update, with particular attention on the EGFRxCD3 engager, CX-904. This candidate is anticipated to deliver Phase 1a data in the second half of 2024, which will guide the subsequent Phase 1b trials planned for 2025. The company has an agreement with Amgen (NASDAQ:AMGN) that includes a co-development option and profit sharing in the United States.

Moreover, CytomX's fully owned assets, CX-2051 and CX-801, are on schedule to begin Phase 1 trials in the first half of 2024. Despite Bristol Myers (NYSE:BMY) Squibb's decision to terminate the program for 98622, an anti-CTLA4 antibody, due to a shift in their portfolio priorities, CytomX has not yet reviewed the data from this program.

The company disclosed that it has $174 million in cash reserves, which is expected to fund operations into the second half of 2025. This financial position provides CytomX with a runway to advance its clinical programs and reach key development milestones in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.